Immunopotentiators in Modern Vaccines

<p>1. Vaccine Adjuvants' Mode of Action: Unraveling ‘‘the Immunologist's Dirty Little Secret”<br>2. The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses<br>3. Dendritic Cells as Targets of Vaccines and Adjuvants<br>4. Host-Derived Cytokines and Chemokines as Vaccine Adjuvants<br>5. Discovery of Immune Potentiators as Vaccine Adjuvants<br>6. Current Status of Toll-Like Receptor 4 Ligand Vaccine Adjuvants<br>7. Flagellins as Adjuvants of Vaccines<br>8. Toll-Like Receptor 7 and 8 Agonists for Vaccine Adjuvant Use<br>9. CpG Oligodeoxynucleotides as Adjuvants for Clinical Use<br>10. Advax Adjuvant: A Potent and Safe Immunopotentiator Composed of Delta Inulin<br>11. Natural Vaccine Adjuvants and Immunopotentiators Derived From Plants, Fungi, Marine Organisms, and Insects<br>12. Polymeric Particles as Vaccine Delivery Systems<br>13. MF59: A Safe and Potent Adjuvant for Human Use<br>14. The Development of the Adjuvant System AS01: A Combination of Two Immunostimulants MPL and QS-21 in Liposomes<br>15. Development and Evaluation of AS04, a Novel and Improved Adjuvant System Containing 3-O-Desacyl-4′- Monophosphoryl Lipid A and Aluminum Salt<br>16. ISCOMATRIX Adjuvant in the Development of Prophylactic and Therapeutic Vaccines<br>17. Development and Evaluation of CAF01<br>18. Mineral Adjuvants<br>19. Toxin-Based Mucosal Adjuvants<br>20. Adjuvants for Skin Vaccination<br>21. Vaccination to Treat Noninfectious Diseases: Surveying the Opportunities<br>22. A Framework for Evaluating Nonclinical Safety of Novel Adjuvants and Adjuvanted Preventive Vaccines</p>